**Product Description**
Nizatel 40 Tablet is an **anti-ulcer and acid-suppressing medicine** used for the treatment of **acid reflux, heartburn, gastric and duodenal ulcers, and gastroesophageal reflux disease (GERD)**. It contains **Famotidine (40 mg)**, a potent **H₂ receptor antagonist** that works by **reducing excess acid production in the stomach**, providing long-lasting relief from acidity and allowing ulcers to heal naturally.
This medicine helps manage symptoms such as **burning sensation in the chest, indigestion, sour taste, and discomfort after meals**. Regular use under medical guidance supports faster recovery from acid-related conditions and prevents their recurrence.
**Key Ingredient**
* **Famotidine (40 mg)** – Blocks histamine receptors in the stomach, effectively reducing acid secretion and promoting ulcer healing.
**Directions for Use**
* Take Nizatel 40 Tablet exactly as prescribed by your doctor.
* Swallow the tablet whole with a glass of water; do not crush or chew.
* It may be taken before bedtime or as advised by your physician.
* Follow the prescribed dosage and duration for best results.
**Safety Information**
* Use only under medical supervision.
* Do not exceed the recommended dose.
* Inform your doctor if you have liver or kidney disease before starting this medicine.
* Avoid alcohol, caffeine, and spicy foods during treatment.
* Not recommended for children unless prescribed by a doctor.
* Store in a cool, dry place away from sunlight and moisture.
**Benefits**
* Provides powerful relief from acidity and heartburn
* Helps in the treatment and prevention of gastric and duodenal ulcers
* Reduces acid reflux and related digestive discomfort
* Promotes faster ulcer healing and digestive comfort
* Offers long-lasting acid control with once-daily dosing
**Product Variants & Keywords**
Nizatel 40 Tablet, Famotidine 40 mg, Nizatel for Acidity, Nizatel for GERD, Nizatel Acid Reflux Tablet, Nizatel Heartburn Medicine, Nizatel Ulcer Treatment, Buy Nizatel 40 Online



Reviews
There are no reviews yet.